EP1506002A4 - Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies - Google Patents

Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Info

Publication number
EP1506002A4
EP1506002A4 EP03753102A EP03753102A EP1506002A4 EP 1506002 A4 EP1506002 A4 EP 1506002A4 EP 03753102 A EP03753102 A EP 03753102A EP 03753102 A EP03753102 A EP 03753102A EP 1506002 A4 EP1506002 A4 EP 1506002A4
Authority
EP
European Patent Office
Prior art keywords
crohn
psoriasis
disease
treatment
gamma antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03753102A
Other languages
German (de)
French (fr)
Other versions
EP1506002A2 (en
Inventor
Rolf Ehrhardt
Dan Levitt
Beth Layug
Don O'neill
Nancy Wedel
Lars Ostberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of EP1506002A2 publication Critical patent/EP1506002A2/en
Publication of EP1506002A4 publication Critical patent/EP1506002A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP03753102A 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies Withdrawn EP1506002A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15074202A 2002-05-17 2002-05-17
US150742 2002-05-17
US38331002P 2002-05-22 2002-05-22
PCT/US2003/015874 WO2003097082A2 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
US383310P 2010-09-15

Publications (2)

Publication Number Publication Date
EP1506002A2 EP1506002A2 (en) 2005-02-16
EP1506002A4 true EP1506002A4 (en) 2006-06-07

Family

ID=29552737

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03753102A Withdrawn EP1506002A4 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Country Status (5)

Country Link
EP (1) EP1506002A4 (en)
JP (1) JP2005529152A (en)
AU (1) AU2003231802A1 (en)
CA (1) CA2486147A1 (en)
WO (1) WO2003097082A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014467A1 (en) 1992-12-29 1994-07-07 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
ATE541859T1 (en) * 2005-01-27 2012-02-15 Novimmune Sa HUMAN ANTI-INTERFERON-GAMMA ANTIBODIES AND METHOD OF USE THEREOF
US20090186047A1 (en) * 2006-04-25 2009-07-23 Intercell Ag HCV Vaccinations
KR20100126515A (en) * 2008-03-18 2010-12-01 아보트 러보러터리즈 Methods for treating psoriasis
CN104159919A (en) 2011-11-23 2014-11-19 安姆根有限公司 Methods of treatment using an antibody against interferon gamma
MA41271A (en) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc METHODS OF USE OF OLIGONUCLEOTIDES ANTISENS TARGETING SMAD7
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
EA037532B1 (en) 2015-05-07 2021-04-08 Новиммун Са Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695189A1 (en) * 1992-12-29 1996-02-07 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US6329511B1 (en) * 1998-12-01 2001-12-11 Protein Design Labs, Inc. Humanized antibodies to γ-interferon
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695189A1 (en) * 1992-12-29 1996-02-07 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US6329511B1 (en) * 1998-12-01 2001-12-11 Protein Design Labs, Inc. Humanized antibodies to γ-interferon
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOMMES ET AL: "Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.", GUT, vol. 55, 2006, pages 1131 - 1137 *
See also references of WO03097082A2 *
STANGE ET AL: "Therapie der entzündlichen Darmerkrankungen", PRAXIS, vol. 91, 2006, pages 2029 - 2039 *
THAKUR A B ET AL: "A POTENT NEUTRALIZING MONOCLONAL ANTIBODY CAN DISCRIMINATE AMONGST IFNGAMMA FROM VARIOUS PRIMATES WITH GREATER SPECIFICITY THAN CAN THE HUMAN IFNGAMMA RECEPTOR COMPLEX", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 36, no. 15/16, 1999, pages 1107 - 1115, XP001159741, ISSN: 0161-5890 *

Also Published As

Publication number Publication date
EP1506002A2 (en) 2005-02-16
AU2003231802A1 (en) 2003-12-02
WO2003097082A3 (en) 2004-12-09
CA2486147A1 (en) 2003-11-27
JP2005529152A (en) 2005-09-29
WO2003097082A2 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
CY2020003I2 (en) ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND USES FOR THE THERAPEUTIC TREATMENT OF CROHN'S DISEASE
HK1204654A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody -il-1r1
EP1416961A4 (en) Composition and method for the treatment of disease
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1589933A4 (en) Compositions and methods for the diagnosis and treatment of tumor
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1572091A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
EP1575571A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
AU2003268295A8 (en) "diagnosis and treatment of infertility"
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
HUP0303236A3 (en) Carbamate compounds for use in the treatment of pain
GB0213869D0 (en) The treatment of pain
EP1506002A4 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
GB0211295D0 (en) Treatment of pain
AU2003248660A8 (en) Treatment of vascular dysfunction and alzheimer's disease
EP1575497A4 (en) Novel composition and methods for the treatment of psoriasis
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
PL377110A1 (en) Prevention and treatment of alzheimer's disease
AU2003228339A8 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
EP1513550A4 (en) Novel bacterium for treatment of disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060508

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/00 20060101ALI20060428BHEP

Ipc: A61P 37/06 20060101ALI20060428BHEP

Ipc: C07K 16/00 20060101ALI20060428BHEP

Ipc: A61K 39/395 20060101ALI20060428BHEP

Ipc: A61K 38/21 20060101AFI20031202BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PDL BIOPHARMA, INC.

17Q First examination report despatched

Effective date: 20070608

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PDL BIOPHARMA, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20090918

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FACET BIOTECH CORPORATION